Halozyme Therapeutics Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2015
Period Ending	Dec '25 Dec 4, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2015
Market Capitalization	6,402	5,875	4,417	7,199	4,976	4,713	Upgrade
Market Cap Growth	24.93%	33.01%	-38.64%	44.69%	5.58%	104.10%	Upgrade
Enterprise Value	7,121	6,714	5,364	8,365	5,031	4,755	Upgrade
PE Ratio	12.61	13.70	17.34	38.06	14.05	44.66	Upgrade
PS Ratio	6.04	5.99	5.89	11.66	12.76	21.54	Upgrade
PB Ratio	14.91	16.72	58.26	45.31	28.73	38.17	Upgrade
P/TBV Ratio	-	-	-	-	28.73	38.17	Upgrade
P/FCF Ratio	12.47	12.99	13.08	32.70	18.99	108.87	Upgrade
P/OCF Ratio	12.29	12.70	12.57	32.04	18.90	103.95	Upgrade
EV/Sales Ratio	6.67	6.85	7.15	13.54	12.91	21.74	Upgrade
EV/EBITDA Ratio	10.08	11.09	14.22	26.60	20.63	39.89	Upgrade
EV/EBIT Ratio	11.23	12.61	17.43	30.89	20.74	40.33	Upgrade
EV/FCF Ratio	13.87	14.84	15.88	37.99	19.20	109.86	Upgrade
Debt / Equity Ratio	3.05	4.22	18.27	9.07	4.47	2.66	Upgrade
Debt / EBITDA Ratio	1.87	2.42	3.59	4.54	3.15	2.71	Upgrade
Debt / FCF Ratio	2.56	3.28	4.10	6.55	2.95	7.59	Upgrade
Asset Turnover	0.57	0.54	0.46	0.45	0.53	0.47	Upgrade
Inventory Turnover	1.65	1.77	2.36	2.67	2.04	1.72	Upgrade
Quick Ratio	1.25	6.50	5.07	4.54	7.10	1.11	Upgrade
Current Ratio	1.59	7.80	6.64	5.65	7.91	1.32	Upgrade
Return on Equity (ROE)	124.50%	198.42%	222.07%	110.23%	231.44%	106.33%	Upgrade
Return on Assets (ROA)	21.24%	18.16%	11.89%	12.28%	20.47%	15.74%	Upgrade
Return on Capital (ROIC)	22.87%	19.61%	12.78%	12.98%	21.16%	17.11%	Upgrade
Return on Capital Employed (ROCE)	53.30%	28.70%	21.00%	16.90%	27.90%	91.00%	Upgrade
Earnings Yield	7.93%	7.30%	5.77%	2.63%	7.12%	2.24%	Upgrade
FCF Yield	8.02%	7.70%	7.65%	3.06%	5.27%	0.92%	Upgrade
Buyback Yield / Dilution	3.31%	3.56%	4.56%	4.21%	-3.77%	1.99%	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.